Manager, New Product Planning

About the role

This high-impact role supports the strategy, planning, and execution of commercial assessments for Genesis’s AI-enabled pipeline programs. The position reports to the Director of New Product Planning and is hybrid, requiring 2-3 days a week at Genesis’s San Diego office.

Responsibilities

• Analyze disease areas, treatment paradigms, and unmet needs to help shape the positioning of new potential drugs.
• Support KOL interviews and secondary research (e.g., epidemiology, published literature) to build and validate commercial assumptions.
• Track competitor pipelines, clinical readouts, approvals, and deals, including monitoring conference abstracts and presentations for early signals, and translate implications into updated assumptions for the team.
• Contribute commercial input into Target Product Profiles (TPPs) and clinical development plans (endpoints, comparators, patient populations, and indication sequencing).
• Work cross-functionally with discovery, preclinical development, business development, and finance to align programs with commercial objectives.

Requirements

• Life sciences background, ideally a BS or MS degree in biology or a related field.
• 1-2 years at a top-tier consulting firm, investment bank, or equity research group (preferred).
• Experience in New Product Planning, marketing, portfolio strategy, competitive intelligence, or a related analytical role at a pharmaceutical or biotech company (also considered).
• Experience in oncology or immunology is a plus.
• Exposure to commercial assessments based on primary and secondary research, ideally for preclinical and early clinical assets.
• Strong Excel modeling and PowerPoint skills.
• Excellent communication, listening, and presentation skills.
• Ability to travel domestically and internationally, if required, approximately 10% of the time.

About Genesis Molecular AI

Genesis Molecular AI is pioneering foundation models for molecular AI to unlock a new era of drug design and development. Our generative and predictive AI platform, GEMS (Genesis Exploration of Molecular Space), integrates AI and physics into industry-leading models to generate and optimize drug molecules, including the breakthrough generative diffusion model Pearl for structure prediction.

Genesis is backed by premier AI and life science investors, including a16z, NVIDIA, Rock Springs Capital, Menlo Ventures, T. Rowe Price, Fidelity, and Radical Ventures. The company has signed category-leading AI-pharma deals, including a significant expansion with Incyte (total potential deal value of several billion dollars). Genesis is headquartered in San Mateo, CA, with a fully integrated laboratory in San Diego.